Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Early Combination Antiretroviral Therapy Limits Exposure to HIV-1 Replication and Cell-Associated HIV-1 DNA Levels in Infants.

McManus M, Mick E, Hudson R, Mofenson LM, Sullivan JL, Somasundaran M, Luzuriaga K; PACTG 356 Investigators.

PLoS One. 2016 Apr 22;11(4):e0154391. doi: 10.1371/journal.pone.0154391. eCollection 2016.

2.

Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.

Herout S, Mandorfer M, Breitenecker F, Reiberger T, Grabmeier-Pfistershammer K, Rieger A, Aichelburg MC.

PLoS One. 2016 Apr 11;11(4):e0152910. doi: 10.1371/journal.pone.0152910. eCollection 2016.

3.

HIV-1 cellular and tissue replication patterns in infected humanized mice.

Araínga M, Su H, Poluektova LY, Gorantla S, Gendelman HE.

Sci Rep. 2016 Mar 21;6:23513. doi: 10.1038/srep23513.

4.

Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.

Stoszko M, De Crignis E, Rokx C, Khalid MM, Lungu C, Palstra RJ, Kan TW, Boucher C, Verbon A, Dykhuizen EC, Mahmoudi T.

EBioMedicine. 2015 Nov 27;3:108-21. doi: 10.1016/j.ebiom.2015.11.047. eCollection 2016 Jan.

5.

Markers of HIV reservoir size and immune activation after treatment in acute HIV infection with and without raltegravir and maraviroc intensification.

Ananworanich J, Chomont N, Fletcher JL, Pinyakorn S, Schuetz A, Sereti I, Rerknimitr R, Dewar R, Kroon E, Vandergeeten C, Trichavaroj R, Chomchey N, Chalermchai T, Michael NL, Kim JH, Phanuphak P, Phanuphak N.

J Virus Erad. 2015;1(2):116-122. Epub 2015 Apr 1.

6.

Measuring the latent reservoir in vivo.

Massanella M, Richman DD.

J Clin Invest. 2016 Feb;126(2):464-72. doi: 10.1172/JCI80567. Epub 2016 Feb 1.

PMID:
26829625
7.

Advances and hope for perinatal HIV remission and cure in children and adolescents.

Rainwater-Lovett K, Uprety P, Persaud D.

Curr Opin Pediatr. 2016 Feb;28(1):86-92. doi: 10.1097/MOP.0000000000000304.

PMID:
26709685
8.

CRISPR-mediated Activation of Latent HIV-1 Expression.

Limsirichai P, Gaj T, Schaffer DV.

Mol Ther. 2016 Mar;24(3):499-507. doi: 10.1038/mt.2015.213. Epub 2015 Nov 26.

PMID:
26607397
9.

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption.

Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, Kuritzkes DR, Lederman MM, Para M, Gandhi RT.

AIDS. 2016 Jan 28;30(3):343-53. doi: 10.1097/QAD.0000000000000953.

PMID:
26588174
10.

No evidence of posttreatment control after early initiation of antiretroviral therapy.

Gianella S, Anderson CM, Richman DD, Smith DM, Little SJ.

AIDS. 2015 Oct 23;29(16):2093-7. doi: 10.1097/QAD.0000000000000816.

PMID:
26544575
11.

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction.

Ostrowski M, Benko E, Yue FY, Kim CJ, Huibner S, Lee T, Singer J, Pankovich J, Laeyendecker O, Kaul R, Kandel G, Kovacs C.

Open Forum Infect Dis. 2015 Sep 22;2(4):ofv138. doi: 10.1093/ofid/ofv138. eCollection 2015 Dec.

12.
13.

A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals.

Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin AG, Strain MC, Richman DD, O'Doherty U, Palmer S, Hecht FM, Hoh R, Barnard RJ, Miller MD, Hazuda DJ, Deeks SG, Sékaly RP, Chomont N.

EBioMedicine. 2015 Jun 27;2(8):874-83. doi: 10.1016/j.ebiom.2015.06.019. eCollection 2015 Aug.

14.

The HIV treatment cascade in acutely infected people: informing global guidelines.

Rutstein SE, Sellers CJ, Ananworanich J, Cohen MS.

Curr Opin HIV AIDS. 2015 Nov;10(6):395-402. doi: 10.1097/COH.0000000000000193.

PMID:
26371460
15.

Early Initiation Rather Than Prolonged Duration of Antiretroviral Therapy in HIV Infection Contributes to the Normalization of CD8 T-Cell Counts.

Cao W, Mehraj V, Trottier B, Baril JG, Leblanc R, Lebouche B, Cox J, Tremblay C, Lu W, Singer J, Li T, Routy JP; Montreal Primary HIV Infection Study Group.

Clin Infect Dis. 2016 Jan 15;62(2):250-7. doi: 10.1093/cid/civ809. Epub 2015 Sep 8.

PMID:
26349551
16.

Developing Combined HIV Vaccine Strategies for a Functional Cure.

Noto A, Trautmann L.

Vaccines (Basel). 2013 Oct 28;1(4):481-96. doi: 10.3390/vaccines1040481. Review.

17.

HIV Replication at Low Copy Number and its Correlation with the HIV Reservoir: A Clinical Perspective.

Sarmati L, D'Ettorre G, Parisi SG, Andreoni M.

Curr HIV Res. 2015;13(3):250-7. Review.

18.

Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies.

Flynn JK, Gorry PR.

Clin Transl Immunology. 2014 Jul 18;3(7):e20. doi: 10.1038/cti.2014.16. eCollection 2014 Jul. Review.

19.

Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation.

Schuetz A, Deleage C, Sereti I, Rerknimitr R, Phanuphak N, Phuang-Ngern Y, Estes JD, Sandler NG, Sukhumvittaya S, Marovich M, Jongrakthaitae S, Akapirat S, Fletscher JL, Kroon E, Dewar R, Trichavaroj R, Chomchey N, Douek DC, O Connell RJ, Ngauy V, Robb ML, Phanuphak P, Michael NL, Excler JL, Kim JH, de Souza MS, Ananworanich J; RV254/SEARCH 010 and RV304/SEARCH 013 Study Groups.

PLoS Pathog. 2014 Dec 11;10(12):e1004543. doi: 10.1371/journal.ppat.1004543. eCollection 2014 Dec.

20.

How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?

Ananworanich J, Dubé K, Chomont N.

Curr Opin HIV AIDS. 2015 Jan;10(1):18-28. doi: 10.1097/COH.0000000000000122. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk